Nrp1-specific antisense oligonucleotides with reduced off-target binding for use in preventing and / or treating cancer

TW202635881APending Publication Date: 2026-09-01SECARNA PHARMA GMBH & CO KG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114140491
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-10-21
Filing Date
2025-10-20
Publication Date
2026-09-01

Smart Images

  • Figure TWG2TA001074417_001
    Figure TWG2TA001074417_001
  • Figure TWG2TA001074417_002
    Figure TWG2TA001074417_002
  • Figure TWG2TA001074417_003
    Figure TWG2TA001074417_003
Patent Text Reader

Abstract

The present invention refers to an oligonucleotide consisting of a core sequence of ATATTTAGGTCCAGCG (SEQ ID NO:1) or AATATTTAGGTCCAGCG (SEQ ID NO:2) and at least one additional nucleotide at the 3'-end and optionally at least one additional nucleotide at the 5'-end. At least one of the nucleotides of the oligonucleotide is modified, and the oligonucleotide binds to pre-mRNA of neuropilin
Need to check novelty before this filing date? Find Prior Art